276702-15-9

276702-15-9 structure

Name: SB 332235
Chemical Name: SB-332235
CAS Number: 276702-15-9
Molecular Formula: C₁₃H₁₀Cl₃N₃O₄S
Molecular Weight: 410.660
Catalog: Signaling Pathways GPCR/G Protein CXCR
Create Date: 2018-07-12 23:00:54
Modify Date: 2024-01-10 18:59:49
SB-332235 is a potent, orally active nonpeptide CXCR2 antagonist, with an IC50 of 7.7 nM. SB-332235 displays 285-fold selectivity for CXCR2 over CXCR1. SB-332235 inhibits acute and chronic models of arthritis in the rabbit. SB-332235 inhibits viability of AML cells[1][2].

Name	SB-332235
Synonyms	6-Chloro-3-{[(2,3-dichlorophenyl)carbamoyl]amino}-2-hydroxybenzenesulfonamide SB-332235 5HLP8UVL8M Benzenesulfonamide, 6-chloro-3-[[[(2,3-dichlorophenyl)amino]carbonyl]amino]-2-hydroxy-

Description	SB-332235 is a potent, orally active nonpeptide CXCR2 antagonist, with an IC50 of 7.7 nM. SB-332235 displays 285-fold selectivity for CXCR2 over CXCR1. SB-332235 inhibits acute and chronic models of arthritis in the rabbit. SB-332235 inhibits viability of AML cells[1][2].
Related Catalog	Signaling Pathways >> GPCR/G Protein >> CXCR Research Areas >> Inflammation/Immunology Signaling Pathways >> Immunology/Inflammation >> CXCR
In Vitro	SB-332235 (1-100 μM; 48 hours) inhibits viability of AML cell lines[2]. Cell Viability Assay[2] Cell Line: AML cell Concentration: 1, 10, 100 μM Incubation Time: 48 hours Result: Led to a dose-dependent decrease in proliferation in all cell lines.
In Vivo	SB-332235 (25 mg/kg, p.o., b.i.d.) exhibits significantly reduced numbers of total leukocytes in synovial fluids from IL-8-injected knees[1]. SB-332235 (10-25 mg/kg; p.o.; twice a day for 14 days) inhibits chronic Ag-induced arthritis[1]. Animal Model: Adult female New Zealand White rabbits (chronic OVA-induced model of arthritis)[1] Dosage: 10, 25 mg/kg Administration: P.o.; twice a day for 14 days Result: Day-15 synovial fluid leukocyte numbers in OVA-injected knees were significantly reduced in rabbits. The decrease in neutrophils, monocytes, and lymphocytes resulting from treatment with 25 mg/kg of the antagonist was accompanied by a significant reduction in synovial fluid PGE2, LTB4, LTC4, and IL-8 levels.
References	[1]. Podolin PL, et al. A potent and selective nonpeptide antagonist of CXCR2 inhibits acute and chronic models of arthritis in the rabbit. J Immunol. 2002;169(11):6435-6444. [2]. Schinke C, et al. IL8-CXCR2 pathway inhibition as a therapeutic strategy against MDS and AML stem cells [published correction appears in Blood. 2015 Jul 16;126(3):425. Barreryo, Laura [corrected to Barreyro, Laura]]. Blood. 2015;125(20):3144-3152.

Density	1.8±0.1 g/cm3
Molecular Formula	C₁₃H₁₀Cl₃N₃O₄S
Molecular Weight	410.660
Exact Mass	408.945770
LogP	3.75
Index of Refraction	1.719
Storage condition	2-8°C

Hazard Codes	Xi

276702-15-9	143797-62-0
201038-74-6	274252-40-3
1346603-08-4	1431697-90-3
200940-23-4	24570-77-2
791789-61-2	201038-58-6
1207032-63-0	1207034-86-3
1158522-08-7	1221715-22-5
940364-43-2	134104-43-1
131615-57-1	6906-52-1
930439-75-1	1241588-65-7